Despite considerable progress on pathogenicity scores prioritizing both coding and noncoding variants for Mendelian disease, little is known about the utility of these pathogenicity scores for common disease. Here, we sought to assess the informativeness of Mendelian disease pathogenicity scores for common disease, and to improve upon existing scores. We first applied stratified LD score regression to assess the informativeness of annotations defined by top variants from published Mendelian disease pathogenicity scores across 41 independent common diseases and complex traits (average N = 320K). Several of the resulting annotations were informative for common disease, even after conditioning on a broad set of coding, conserved, regulatory and LD-related annotations from the baseline-LD model. We then improved upon the published pathogenicity scores by developing AnnotBoost, a gradient boosting-based framework to impute and denoise pathogenicity scores using functional annotations from the baseline-LD model. AnnotBoost substantially increased the informativeness for common disease of both previously uninformative and previously informative pathogenicity scores; our combined joint model included 3 published and 8 boosted scores. The boosted scores also significantly outperformed the corresponding published scores in classifying disease-associated, fine-mapped SNPs.
Introduction
Despite considerable progress on pathogenicity scores prioritizing both coding and non-coding variants for Mendelian disease [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] (reviewed in ref. 11) , little is known about the utility of these pathogenicity scores for common disease. The shared genetic architecture between Mendelian disease and common disease has been implicated in studies reporting the impact of genes underlying monogenic forms of common diseases on the corresponding common diseases 12 , significant cormobidities among Mendelian and complex diseases 13 , and gene-level overlap between Mendelian diseases and cardiovascular diseases [14] [15] [16] , neurodevelopmental traits 17, 18 , and other complex traits 19 .
However, variant-level assessment of shared genetic architecture using Mendelian pathogenicity scores has not been explored. Thus, our current understanding of the genetic relationship between Mendelian disease and common disease remains limited.
Here, we sought to assess the informativeness of Mendelian disease pathogenicity scores for common disease, and to improve upon existing scores. We focused our attention on polygenic common and low-frequency variant architectures, which explain the bulk of common disease heritability [20] [21] [22] [23] [24] . We assessed the informativeness of annotations defined by top variants from published Mendelian disease pathogenicity scores by applying stratified LD score regression 25 (S-LDSC) with the baseline-LD model 26, 27 to 41 independent common diseases and complex traits (average N = 320K). We assessed informativeness conditional on the baseline-LD model, which includes a broad set of coding, conserved, regulatory and LD-related annotations.
We improved upon the published pathogenicity scores by developing AnnotBoost, a gradient boosting-based machine learning framework to impute and denoise pathogenicity scores using functional annotations from the baseline-LD model. We assessed the informativeness of annotations defined by top variants from the boosted scores by applying S-LDSC and assessing informativeness conditional on annotations from the baseline-LD model as well as annotations derived from the corresponding published scores. We also assessed the informativeness of the published and boosted pathogenicity scores in predicting disease-associated, fine-mapped SNPs.
Results

Overview of methods
We define a binary annotation as an assignment of a binary value (0 or 1) to each SNP with minor allele count ≥ 5 in a 1000 Genomes Project European reference panel 28 , as in our previous work 25 . We define a pathogenicity score as an assignment of a numeric value quantifying predicted pathogenicity to some or all of these SNPs; we analyze 11 Mendelian missense scores, 6 genome-wide Mendelian scores, and 18 additional scores. Our primary focus is on binary annotations defined either using top variants from published (missense or genome-wide) Mendelian disease pathogenicity scores, or using top variants from boosted scores that we constructed from those pathogenicity scores using AnnotBoost, a gradient boosting-based framework that we developed to impute and denoise pathogenicity scores using coding, conserved, regulatory and LD-related annotations from the baseline-LD model 26, 27 (see Methods). AnnotBoost uses decision trees to distinguish pathogenic variants (defined using the input pathogenicity score) from benign variants; the AnnotBoost model is trained using the XGBoost gradient boosting software 29 (see URLs). AnnotBoost uses odd (resp. even) chromosomes as training data to make predictions for even (resp. odd) chromosomes; the output of AnnotBoost is the predicted probability of being pathogenic. Further details are provided in the Methods section; we have publicly released open-source software implementing AnnotBoost, as well as all pathogenicity scores and binary annotations analyzed in this work (see URLs).
We assessed the informativeness of the resulting binary annotations for common disease heritability by applying S-LDSC 25 to 41 independent common diseases and complex traits 30 (average N = 320K; Table S1 ; see URLs), conditioned on coding, conserved, regulatory and LD-related annotations from the baseline-LD model 26, 27 and meta-analyzing results across traits. We assessed informativeness for common disease using standardized effect size (τ * ), defined as the proportionate change in per-SNP heritability associated to a one standard deviation increase in the value of the annotation, conditional on other annotations 26 (see Methods). We also computed the heritability enrichment, defined as the proportion of heritability divided by the proportion of SNPs. Unlike enrichment, τ * quantifies effects that are unique to the focal annotation (see Methods). We also assessed the informativeness of the underlying (published and/or boosted) pathogenicity scores in predicting disease-associated, fine-mapped SNPs.
Informativeness of Mendelian missense scores for common disease
We assessed the informativeness for common disease of binary annotations derived from 11 Mendelian disease pathogenicity scores for missense variants 1, [5] [6] [7] [8] [31] [32] [33] [34] [35] (see Table 1 ). These scores reflect the predicted impact of missense mutations on Mendelian disease and were trained using rare variants, primarily from ClinVar 36 and Human Gene Mutation Database (HGMD) 37 . For each of the 11 missense scores, we constructed binary annotations based on top missense variants using 5 different thresholds (from top 50% to top 10% of missense variants) and applied S-LDSC 25,26 to 41 independent common diseases and complex traits (Table S1) , conditioning on coding, conserved, regulatory and LD-related annotations from the baseline-LD model 26, 27 and meta-analyzing results across traits; proportions of top SNPs were optimized to maximize informativeness (see Methods).
We incorporated the 5 different thresholds into the number of hypotheses tested when assessing statistical significance (Bonferroni P < 0.05/500 = 0.0001, based on a total of ≈ 500 hypotheses tested in this study; see Methods). We identified (Bonferroni-significant) conditionally informative binary annotations derived from 2 published missense scores: the top 30% of SNPs from MPC 34 Table 2 and Table S2 ). The MPC (Missense badness, PolyPhen-2, and Constraint) score 34 is computed by identifying regions within genes that are depleted for missense variants in ExAC data 38 and incorporating variant-level metrics to predict the impact of missense variants; the PrimateAI score 8 is computed by eliminating common missense variants identified in other primate species (which are presumed to be benign in humans), incorporating a deep learning model trained on the amino acid sequence flanking the variant of interest and the orthologous sequence alignments in other species. The remaining published Mendelian missense scores all had derived binary annotations that were significantly enriched for disease heritability (after Bonferroni correction) but not conditionally informative (except for the published M-CAP score, which spanned too few SNPs to be included in the S-LDSC analysis).
We constructed boosted scores from the 11 Mendelian missense scores using AnnotBoost, a gradient boosting-based machine learning framework that we developed to impute and denoise pathogenicity scores using functional annotations from the baseline-LD model 26 (see Methods).
We note that AnnotBoost scores genome-wide (missense and non-missense) variants, implying low genome-wide correlations between input Mendelian missense scores and corresponding genome-wide boosted scores (0.02-0.24; Table S3A ). AnnotBoost attained high predictive accuracy in out-ofsample predictions of input missense scores (AUROC= 0.76-0.94, AUPRC= 0.43-0.82; Table S4 ), although we caution that high predictive accuracy does not necessarily translate into conditional informativeness for common disease 39 . We further note that out-of-sample AUROCs closely tracked the genome-wide correlations between input Mendelian missense scores and corresponding genomewide boosted scores (r = 0.65), implying that accurately predicting the input pathogenicity scores results in more correlated boosted scores.
For each missense pathogenicity score, after running AnnotBoost, we constructed binary annotations based on top genome-wide variants, using 6 different thresholds (ranging from top 10% to top 0.1% of genome-wide variants, as well as variants with boosted scores ≥ 0.5; see Methods). We assessed the informativeness for common disease of binary annotations derived from each of the 11 boosted scores using S-LDSC, conditioning on annotations from the baseline-LD model and 5 binary annotations derived from the corresponding published Mendelian missense score (using all 5 thresholds) (baseline-LD+5). We identified conditionally informative binary annotations derived from boosted versions of 10 Mendelian missense scores, including 8 previously uninformative scores and the 2 previously informative scores ( Figure 1 , Table 2 and Table S2 ). Letting ↑ denote boosted scores, examples include the top 0.1% of SNPs from M-CAP↑ 7 , a previously uninformative score (enrichment = 23x (s.e. 2.6), τ * = 0.43 (s.e. 0.08); the published M-CAP pathogenicity score spanned too few SNPs to be included in the S-LDSC analysis of Figure 1 ) and the top 0.1% of SNPs from PrimateAI↑ 7 , a previously informative score (enrichment = 35x (s.e. 2.7), τ * = 0.83 (s.e. 0.08)). The M-CAP (Mendelian Clinically Applicable Pathogenicity) score 7 is computed by training a gradient boosting tree classifier to distinguish pathogenic variants from HGMD 37 vs. benign variants from ExAC 38 using 9 pathogenicity likelihood scores as features (including PolyPhen-2 1 , MetaLR 32 , CADD 2 ; see Table 1 ); the PrimateAI score is described above. Interestingly, binary annotations derived from 7 boosted scores had significantly negative τ * (−0.72 (s.e. 0.07)) to −0.13 (s.e. 0.01)). All but one of these binary annotations were significantly enriched for disease heritability, but less enriched than expected based on annotations from the baseline-LD+5 model (Table S5 ; see ref. 40 and Methods), and thus uniquely informative for disease heritability (analogous to transposable element annotations in ref. 40 that were significantly depleted, but less depleted than expected and thus uniquely informative). The boosted version of the remaining Mendelian missense score (MVP↑; not included in Figure 1 ) had a derived binary annotation that was significantly enriched for disease heritability (after Bonferroni correction) but not conditionally informative (Table S2 ).
We performed two secondary analyses. First, we restricted the 10 significant binary annotations derived from our boosted Mendelian missense scores to non-coding regions, which were previously unscored by the Mendelian missense scores, and assessed the informativeness of the resulting non-coding binary annotations using S-LDSC. We determined that the non-coding annotations retained the bulk of the overall signals (85%-110% of absolute τ * ; Table S6 ), implying that AnnotBoost leverages information about pathogenic missense variants to usefully impute scores for non-missense variants. Second, we investigated which features of the baseline-LD model contributed the most to the informativeness of the boosted annotations by applying Shapley Additive Explanation (SHAP) 41 , a widely used tool for interpreting machine-learning models. We determined that conservation-related features drove the predictions of the boosted annotations, particularly (binary and continuous) GERP scores 42 ( Figure S1 ).
Informativeness of genome-wide Mendelian pathogenicity scores for common disease
We assessed the informativeness for common disease of binary annotations derived from 6 genomewide Mendelian disease pathogenicity scores 2-4,9,10 (see Table 1 ). These scores reflect the predicted impact of (coding and) non-coding variants on Mendelian disease and were also primarily trained using rare variants from ClinVar 36 and HGMD 37 . For each of the 6 genome-wide scores, we constructed binary annotations based on top genome-wide variants using 5 different thresholds (from top 0.1% to top 10% of genome-wide variants) and applied S-LDSC to the 41 traits, conditioning on the baseline-LD model 26 and meta-analyzing results across traits; proportions of top SNPs were optimized to maximize informativeness (see Methods). We identified (Bonferroni-significant) conditionally informative binary annotations derived from 3 genome-wide scores: the top 0.5% of Table 2 and Table S7 ). The CADD (Combined Annotation Dependent Depletion) score 2, 43 is computed by training a support vector machine to distinguish deleterious vs. neutral variants using functional annotations as features; the Eigen score 3 is computed from 29 input functional annotations by using an unsupervised machine learning method (leveraging blockwise conditional independence between annotations) to differentiate functional vs. non-functional variants; the ReMM (Regulatory Mendelian Mutation) score 4 is computed by training a random forest classifier to distinguish 406 hand-curated Mendelian mutations from neutral variants using conservation scores and functional annotations as features.
The remaining 3 genome-wide scores all had derived binary annotations that were significantly enriched for disease heritability (after Bonferroni correction) but not conditionally informative (Table   S7 ).
We applied AnnotBoost to the 6 genome-wide Mendelian scores. We observed moderate correlations between input genome-wide Mendelian scores and corresponding boosted scores (r = 0.35-0.66; Table S3B ). AnnotBoost again attained high predictive accuracy in out-of-sample predictions of input genome-wide scores (AUROC = 0.83-1.00, AUPRC = 0.70-1.00; Table S4 ); however, outof-sample AUROCs did not closely track the correlations between input genome-wide scores and corresponding boosted scores (r = 0.05).
We again constructed binary annotations based on top genome-wide variants, using 6 different thresholds (ranging from top 0.1% to top 10% of genome-wide variants, as well as variants with boosted scores ≥ 0.5; see Methods). We assessed the informativeness for common disease of binary annotations derived from each of the 6 boosted scores using S-LDSC, conditioning on annotations from the baseline-LD model and 5 binary annotations derived from the corresponding published genome-wide Mendelian score (using all 5 thresholds). We identified conditionally informative binary annotations derived from boosted versions of all 6 genome-wide Mendelian scores, including the 3 previously uninformative scores and the 3 previously informative scores ( Figure 2 , Table 2 and Table S2 ). Examples include the top 5% of SNPs from ncER↑ 9 (enrichment = 6.2x (s.e. 0.30), τ * = 0.74 (s.e. 0.10)) and the top 0.5% of SNPs from boosted Eigen-PC↑ 3 (enrichment = 16x (s.e. 1.1), τ * = 0.62 (s.e. 0.12)), both of which were previously uninformative scores, and the top 1% of SNPs from ReMM↑ 4 (enrichment = 17x (s.e. 0.8), τ * = 1.17 (s.e. 0.12)), a previously informative score. The ncER (non-coding Essential Regulation) score 9 is computed by training a gradient boosting tree classifier to distinguish non-coding pathogenic variants from ClinVar 36 and HGMD 37 vs. benign variants using 38 functional and structural features; the Eigen-PC score 3 (related to the Eigen score) is computed from 29 input functional annotations by using the lead eigenvector of the annotation covariance matrix to weight the annotations; the ReMM score is described above.
We performed two secondary analyses. First, for the 4 genome-wide Mendelian scores with <100% of SNPs scored (Table 1) , we restricted the binary annotations derived from our boosted genome-wide Mendelian scores to previously unscored variants and assessed the informativeness of the resulting binary annotations using S-LDSC. We determined that these annotations retained only a minority of the overall signals (17%-54% of absolute τ * ; Table S8 ), implying that AnnotBoost usefully denoises previously scored variants. Second, we again investigated which features of the baseline-LD model contributed the most to the informativeness of the boosted annotations by applying SHAP 41 . We determined that both conservation-related features (e.g. GERP scores) and LD-related features (e.g. LLD-AFR; level of LD in Africans) drove the predictions of the boosted annotations ( Figure S2 ).
Informativeness of additional genome-wide scores for common disease
For completeness, we assessed the informativeness for common disease of 18 additional genomewide scores not directly related to Mendelian disease, including 2 constraint-related scores 44,45 , 9 scores based on deep learning predictions of epigenetic marks 46-48 , and 7 gene-based scores 38, [49] [50] [51] (see Table S9 ). For each of the 18 additional scores, we constructed binary annotations based on top variants using 5 different thresholds and applied S-LDSC to the 41 traits, conditioning on the baseline-LD model 26 and meta-analyzing results across traits; in this analysis, we also conditioned on 8 Roadmap annotations 52 (4 annotations based on the union across cell types and 4 annotations based on the average across cell types, as in ref. 39) , as many of the additional scores pertain to regulatory elements, making this an appropriate conservative step.
We identified (Bonferroni-significant) conditionally binary annotations derived from 6 informa- Table 2 and Table S10 ). CDTS (Context-Dependent Tolerance Score) 44 is a constraint score based on observed vs. expected variation in whole-genome sequence data; DeepSEA-H3K4me3 scores 46, 47 are computed by training a deep learning model to predict chromatin marks using proximal reference genome sequence as features and aggregated across different cell types 39 (The DeepSEA annotations in Figure 3 were more significant than those analyzed in ref. 39 , because we optimized binary annotations based on top variants; however, no DeepSEA annotations were included in our combined joint model (see below)). 9 of the remaining 10 scores (excluding two that were not analyzed due to small annotation size) had derived binary annotations that were significantly enriched for disease heritability (after Bonferroni correction) but not conditionally informative (Table S10 ).
We applied AnnotBoost to the 18 additional scores, and to the 47 main annotations of the baseline-LD model (Table S9 ). Correlations between input scores and corresponding boosted scores varied widely (r = 0.005-0.93; Table S3C ). AnnotBoost again attained high predictive accuracy in out-of-sample predictions of the input scores (AUROC = 0.55-1.00, AUPRC = 0.23-0.98; Table S4 ); out-of-sample AUROCs closely tracked the correlations between input scores and corresponding boosted scores (r = 0.65).
We again constructed binary annotations based on top genome-wide variants, using 6 different thresholds (ranging from top 0.1% to top 10% of genome-wide variants, as well as variants with boosted scores ≥ 0.5; see Methods). We assessed the informativeness for common disease of binary annotations derived from each of the 65 boosted scores using S-LDSC, conditioning on annotations from the baseline-LD model, the 8 Roadmap annotations, and (for the first 18 additional scores only) 5 binary annotations derived from the corresponding input scores (using all 5 thresholds).
We identified conditionally informative binary annotations derived from boosted versions of 13/18 additional scores (including 11 previously uninformative scores and 2 previously informative scores) and 24/47 baseline-LD model annotations (Figure 3 , Table 2 and Table S10) 45 is a constraint score based on observed vs. expected variation in whole-exome sequence data; DeepSEA scores are described above. We note that the 18 additional scores included 7 gene-based scores, which did not perform well; 3 published gene-based scores and 4 boosted gene-based scores yielded conditionally significant binary annotations, but their τ * were small (−0.02 to 0.09). Boosted versions of 3 of the remaining 5 additional scores and 20 of the remaining 23 baseline-LD model annotations had derived binary annotations that were significantly enriched for disease heritability (after Bonferroni correction) but not conditionally informative (Table S10 ).
We performed 3 secondary analyses. First, for the 31 additional boosted scores which were marginally significant and for which the underlying published scores had < 100% of SNPs scored, we restricted the boosted scores to previously unscored variants and assessed the informativeness of the resulting binary annotations using S-LDSC. We determined that these annotations retained over half of the overall signals (average of 55% of absolute τ * ; Table S11), implying that AnnotBoost both imputes and denoises existing scores. Second, we again investigated which features of the baseline-LD model contributed the most to the informativeness of the boosted annotations by applying SHAP 41 . We determined that both conservation-related features (e.g. GERP scores) and LD-related features (e.g. LLD-AFR; level of LD in Africans) often drove the predictions of the boosted annotations, although results varied with the type of annotation ( Figure S3 ). Third, we repeated the analyses of Figure 3 without including the 8 Roadmap annotations. We determined that the number of significant binary annotations increased (Table S12 ), confirming the importance of conditioning on the 8 Roadmap annotations as an appropriate conservative step 39 . We further verified that including the 8 Roadmap annotations did not impact results from previous sections (Table S13 ).
Classification of fine-mapped disease SNPs
We assessed the accuracy of the published and boosted scores listed in Table 2 in classifying 8,294 fine-mapped SNPs for 21 autoimmune diseases from Farh et al. 54 (defined by including all SNPs in 95% credible sets) vs. all other ∼10 million common and low-frequency SNPs (see Methods).
We performed two analyses. In the first analysis (single-score analysis), we computed the AUROC individually attained by each of the 82 published and 82 boosted scores, comparing results for boosted scores vs. the corresponding published scores. In the second analysis (multi-score analysis), we computed the AUROC jointly attained by the baseline-LD model, 11 marginally significant published scores, and/or 53 marginally significant boosted scores (see Table 2 ), aggregated by training a gradient boosting model; we used odd (resp. even) chromosomes as training data to make predictions for even (resp. odd) chromosomes (see Methods). We note that this gradient boosting model uses disease data (fine-mapped SNPs), whereas AnnotBoost does not use disease data to construct boosted pathogenicity scores.
Results of the single-score analysis are reported in Figure 4A and Table S14 . We determined that the boosted scores significantly outperformed the corresponding published scores, with an average improvement in AUROC of 0.05. AUROC results for published and boosted scores were moderately correlated with S-LDSC results for binary annotations derived from these scores, validating the S-LDSC results (Table S15 ). We also computed values of AUPRC, which were close to 0 for both SNP sets (Table S15) , as expected since false discovery rate is much higher than false positive rate in highly skewed data sets; this underscores the challenges of accurately classifying fine-mapped disease SNPs without directly using disease data.
Results of the multi-score analysis are reported in Figure 4B and Table S16 . (Table S17 ). As in the single-score analysis, values of AUPRC were close to 0 for both SNP sets (Table S16 ).
We performed 3 secondary analyses. First, we repeated the single-score analysis using 3 additional sets of fine-mapped or disease-associated SNPs: 1,851 fine-mapped SNPs for 47 UK Biobank traits from Weissbrod et al. 55 Figure S4 and Table S16 ). Second, we repeated the multi-score analysis using the 3 additional sets of fine-mapped or disease-associated SNPs.
Adding the 53 boosted annotations to the baseline-LD model plus 11 published annotations produced a significant improvement in AUROC for the de novo SNPs, but not for the Weissbrod et al.
fine-mapped SNPs or NHGRI GWAS SNPs, perhaps because the AUROC was already very high for the Weissbrod et al. fine-mapped SNPs (0.936) and because most NHGRI GWAS SNPs are not causal SNPs ( Figure S5 and Table S16 ). We repeated the multi-score analysis of Weissbrod et al. fine-mapped SNPs using 1,853 SNPs that were fine-mapped without using functional information 55 (to ensure that results were not circular), and obtained similar results (Table S16 ). Third, we repeated the multi-score analysis using all 35 published scores (excluding baseline-LD model annotations) and 82 boosted scores from Table 2 (not just those that were marginally significant), and obtained similar results for all 4 SNP sets (Table S16 ).
Combined joint model
We jointly analyzed the 64 binary annotations (derived from 11 published scores and 53 boosted scores) that were marginally significant in our marginal analyses ( Table 2) Table 2 and Table S18 ). These 11 annotations are each substantially uniquely informative for common disease and include 5 boosted annotations with τ * > 0.5 (e.g.
boosted ReMM: τ * = 1.33 (s.e. 0.12)); annotations with τ * > 0.5 are unusual, and considered to be very important 40 . We note that the top 0.5% of SNPs from REVEL↑ 6 had significantly negative τ * (−0.95 (s.e. 0.08)), as the annotation was significantly enriched for disease heritability but less enriched than expected based on annotations from the combined joint model. We performed 3 secondary analyses. First, we computed genome-wide correlations between the 11 jointly significant annotations and baseline-LD model annotations (Table S19 ). Several of the jointly significant annotations were strongly correlated (up to 0.73) with conservation-related annotations from the baseline-LD model, particularly binary GERP scores, consistent with our SHAP results ( Figure S1 , Figure S2 and Figure S3 ). Second, we compared the informativeness of the baseline-LD model and the combined joint model. We identified the addition of 11 jointly significant annotations greatly reduced the informativeness of several existing baseline-LD annotations, including conservation-related annotations (e.g. conserved primate, binary GERP scores) and other annotations (e.g. coding, CpG content; see Figure S6 and Table S20 ), recapitulating the informativeness of 11 jointly significant annotations. Third, we repeated our multi-score AUROC analysis ( Figure 4B and Table S16) using only the 3 published and 8 boosted scores that were jointly significant, and obtained similar results for all 4 SNP sets (Table S16 ).
Discussion
We analyzed the informativeness of a broad set of Mendelian pathogenicity scores across 41 independent common diseases and complex traits to show that several annotations derived from published Mendelian pathogenicity scores were conditionally informative for common disease after conditioning on the baseline-LD model. We further developed AnnotBoost, a gradient boostingbased machine learning framework to impute and denoise existing pathogenicty scores. We determined that annotations derived from boosted pathogenicity scores were even more informative for common disease, resulting in 11 jointly significant annotations in our combined joint model. Our boosted pathogenicity scores also outperformed the corresponding published scores in classifying disease-associated, fine-mapped SNPs, even when conditioning on the baseline-LD model. These
variant-level results are substantially different from previous studies of gene-level overlap between
Mendelian diseases and complex traits [12] [13] [14] [15] [16] [17] [18] [19] .
We note three key differences between AnnotBoost and previous approaches that utilized gradient boosting to identify pathogenic missense 7 and non-coding variants 9,10 . First, AnnotBoost uses a pathogenicity score as the only input and does not use disease data (e.g. ClinVar 36 or HGMD 37 ). Second, AnnotBoost produces genome-wide scores, even when some SNPs are unscored by the input pathogenicity score. Third, AnnotBoost leverages 75 diverse features from the baseline-LD model 26, 27 , significantly more than previous approaches 7, 9, 10 . Indeed, we determined that AnnotBoost produces strong signals even when conditioned on those approaches.
Our findings have several ramifications for improving our understanding of common disease.
First, it is of interest to assess the informativeness for common disease of Mendelian disease pathogenicity scores that may be developed in the future, particularly after imputing and denoising these scores using AnnotBoost. Second, annotations derived from published and boosted Mendelian pathogenicity scores can be used to improve functionally informed fine-mapping 55, 58, 59 , as well as polygenic risk prediction 60, 61 and association mapping 62 . Third, elucidating specific mechanistic links between Mendelian disease and common disease may yield important biological insights.
We note several imitations of our work. First, while we showed that annotations derived from Mendelian disease pathogenicity scores are informative for common disease, we focused on common and low-frequency variants and did not analyze Mendelian diseases. Second, S-LDSC is not wellsuited to analysis of annotations spanning a very small proportion of the genome, preventing the analysis of a subset of published pathogenicity scores; nonetheless, our main results attained high statistical significance. Third, the gene-based scores that we analyzed did not perform well, perhaps because they were defined using 100kb windows, a crude strategy employed in previous work 30,50,63 ; better strategies for linking regulatory variants to genes 64,65 could potentially improve upon those results. Despite these limitations, the imputed and denoised pathogenicity scores produced by our AnnotBoost framework have high potential to improve gene discovery and fine-mapping for common disease.
Methods
Genomic annotations and the baseline-LD model
We define a genomic annotation as an assignment of a numeric value to each SNP above a specified minor allele frequency (e.g. minor allele count ≥ 5) in a predefined reference panel (e.g. 1000
Genomes 28 ; see URLs). Continuous-valued annotations can have any real value. Probabilistic annotations can have any real value between 0 and 1. Binary annotations can have value 0 or 1 only. A binary annotation can be viewed as a subset of SNPs (the set of SNPs with annotation value 1); we note all annotations analyzed in this work are binary annotations. Annotations that correspond to known or predicted function are referred to as functional annotations.
The baseline-LD model 26 (v2.1) contains 86 functional annotations (see URLs). We use these annotations as features of AnnotBoost (see below). These annotations include genomic elements (e.g. coding, enhancer, promoter), conservation (e.g. GERP, PhastCon), regulatory elements (e.g. histone marks, DNaseI-hypersensitive sites (DHS), transcription factor (TF) binding sites), and linkage disequilibrium (LD)-related annotations (e.g. predicted allele age, recombination rate, SNPs with low levels of LD).
Enrichment and τ * metrics
We used stratified LD score regression (S-LDSC 25, 26 ) to assess the contribution of an annotation to disease heritability by estimating the enrichment and the standardized effect size (τ * ) of an annotation.
Let a cj represent the (binary or probabilistic) annotation value of the SNP j for the annotation c.
S-LDSC assumes the variance of per normalized genotype effect sizes is a linear additive contribution
to the annotation c:
where τ c is the per-SNP contribution of the annotation c. S-LDSC estimates τ c using the following equation:
where N is the sample size of the GWAS and (j, c) is the LD score of the SNP j to the annotation c. The LD score is computed as follow (j, c) = k a ck r 2 jk where r jk is the correlation between the SNPs j and k.
We used two metrics to assess the informativeness of an annotation. First, the standardized effect size (τ * ), the proportionate change in per-SNP heritability associated with a one standard deviation increase in the value of the annotation (conditional on all the other annotations in the model), is defined as follows:
where sd(C) is the standard deviation of the annotation c, h 2 g is the estimated SNP-heritability, and M is the number of variants used to compute h 2 g (in our experiment, M is equal to 5,961,159, the number of common SNPs in the reference panel). The significance for the effect size for each annotation, as mentioned in previous studies 26, 30, 50 , is computed as ( τ * se(τ * ) ∼ N (0, 1)), assuming that τ * se(τ * ) follows a normal distribution with zero mean and unit variance.
Second, enrichment of the binary and probabilistic annotation is the fraction of heritability explained by SNPs in the annotation divided by the proportion of SNPs in the annotation, as shown below:
where h 2 g (C) is the heritability captured by the cth annotation. When the annotation is enriched for trait heritability, the enrichment is > 1; the overlap is greater than one would expect given the trait heritablity and the size of the annotation. The significance for enrichment is computed using the block jackknife as mentioned in previous studies 25, 30, 50, 63 .). The key difference between enrichment and τ * is that τ * quantifies effects that are unique to the focal annotation after conditioning on all the other annotations in the model, while enrichment quantifies effects that are unique and/or non-unique to the focal annotation.
In all our analyses, we used the European samples in 1000G 28 (see URLs) as reference SNPs.
Regression SNPs were obtained from HapMap 3 66 (see URLs). SNPs with marginal association statistics > 80 and SNPs in the major histocompatibility complex (MHC) region were excluded.
Unless stated otherwise, we included the baseline-LD model 26 in all primary analyses using S-LDSC, both to minimize the risk of bias in enrichment estimates due to model mis-specification 25, 26 and to estimate effect sizes (τ * ) conditional on known functional annotations.
Published Mendelian pathogenicity scores
We considered a total 35 published scores: 11 Mendelian missense pathogenicity scores, 6 genomewide Mendelian pathogenicity scores, and 18 additional scores (see Table 1 and Table S9 ). Here, we provide a short description for Mendelian missense and genome-wide Mendelian pathogenicity scores. Details for 18 additional scores and the baseline-LD annotations are provided in Table S9 .
Our curated pathogenicity scores are available online (see URLs).
For all scores, we constructed annotations using GRCh37 assembly limited to all 9,997,231 low-frequency and common SNPs (with minor allele frequency (MAF) >= 0.05%) found in 1000
Genomes 28 European Phase 3 reference genome individuals (see URLs). Mendelian missense scores were readily available from dbNSFP database 67,68 using a rankscore (a converted score based on the rank among scored SNPs); genome-wide Mendealian scores were individually downloaded and used with no modification to original scores (see URLs). For each pathogenicity score, we constructed a binary annotation based on optimized threshold (See below). Short descriptions for each pathogenicity score (excluding 18 additional scores and the baseline-LD annotations; provided in Table S9 ) are provided below:
Mendelian missense pathogenicity scores: 
AnnotBoost framework
AnnotBoost is based on gradient boosting, a machine learning method for classification; the Annot-Boost model is trained using the XGBoost gradient boosting software 29 (see URLs). AnnotBoost requires only one input, a pathogenicity score to boost, and generates a genome-wide (probabilistic) pathogenicity score. During the training, AnnotBoost uses decision trees, where each node in a tree splits SNPs into two classes (pathogenic and benign) using 75 coding, conserved, regulatory, and LD-related features from the baseline-LD model 26 (excluding 10 MAF bins features; we obtained similar results with or without MAF bins features; see Figure S7 ). The method generates training data from the input pathogenicity scores without using external variant data; top 10% SNPs from the input pathogenicity score are labeled as a positive training set, and bottom 40% SNPs are labeled as a control training set; we obtained similar results with other training data ratios (see Figure S8 ). As described in ref. 29 , the prediction is based on T additive estimators (we use T =
where l is a differentiable convex loss function (which measures the difference between the prediction (ŷ i ) and the target y i at the i-th instance), f t is an independent tree structure, and last term γ(f t ) penalizes the complexity of the model, helping to avoid over-fitting. The prediction (ŷ i ) is made by We used the following model parameters: the number of estimators (200, 250, 300), depth of the tree (25, 30, 35) , learning rate (0.05), gamma (minimum loss reduction required before additional partitioning on a leaf node; 10), minimum child weight (6, 8 ,10) , and subsample (0.6, 0.8, 1);
we optimized parameters with hyperparamters tuning (a randomized search) with five-fold crossvalidation. Two important parameters to avoid over-fitting are gamma and learning rate; we chose these values consistent with previous studies 9, 10 . The model with the highest AUROCs on the held-out data was selected and used to make a prediction.
To identify which feature(s) drives the prediction output with less bias, AnnotBoost uses Shapley Addictive Explanation (SHAP 41 ), a widely used tool to interpret complex non-linear models, instead of built-in feature importance tool. SHAP uses the training matrix (features x SNP labels) and the trained model to generate a signed impact of each baseline-LD features on the AnnotBoost prediction.
To evaluate the performance of classifiers, we plotted receiver operating characteristic (ROC) and precision-recall (PR) curves. As we train AnnotBoost by splitting SNPs into odd and even chromosomes, we report the average out-of-sample area under the curve (AUC) of the odd and even chromosomes classifier. We used the threshold of 0.5 to define a class; that is, class 1 includes SNPs with the output probability > 0.5. We caution that high classification accuracy does not necessarily translate into conditional informativeness for common disease 39 .
Constructing binary annotations using top variants from published and boosted scores
For published Mendelian missense pathogenicity scores, we considered five different thresholds to construct binary annotations: top 50%, 40%, 30%, 20% or 10% of scored variants. For published scores that produce Bonferroni-significant binary annotations, we report results for the binary annotation with largest |τ * | among those that are Bonferroni-significant. For published scores that do not produce Bonferroni-significant binary annotations, we report results for the threshold with most significant τ * (even though not Bonferroni-significant).
For all other published pathogenicity scores, we considered the top 10%, 5%, 1%, 0.5% or 0.1% of scored variants to construct binary annotations; we used more inclusive thresholds for published
Mendelian missense pathogenicity scores due to the small proportion of variants scored (∼ 0.3%; see Table 1 ). For published scores that produce Bonferroni-significant binary annotations, we report results for the binary annotation with largest |τ * | among those that are Bonferroni-significant. For published scores that do not produce Bonferroni-significant binary annotations, we report results for the top 5% of variants (the average optimized proportion among Bonferroni-significant binary annotations); we made this choice because (in contrast to published Mendelian missense scores) for many other published scores the most significant τ * was not even weakly significant.
For boosted pathogenicity scores, we considered the top 10%, 5%, 1%, 0.5% or 0.1% of scored variants, as well as variants with boosted scores ≥ 0.5; we note that top 10% of SNPs does not necessarily translate to 10% of SNPs, as some SNPs share the same score, and some genomic regions (e.g. MHC) are excluded when running S-LDSC (see below). For boosted scores that produce Bonferroni-significant binary annotations, we report results for the binary annotation with largest |τ * | among those that are Bonferroni-significant. For boosted scores that do not produce Bonferroni-significant binary annotations, we report results for the top 5% of variants.
In all analyses, we excluded binary annotations with proportion of SNPs < 0.02% (the same threshold used in ref. 50) , because S-LDSC does not perform well for small annotations 25 .
In all primary analyses, we analyzed only binary annotations. However, we verified in a secondary analysis of the CDTS score 44 that probabilistic annotations produced results similar to binary annotations (see Figure S9 ).
Classification of fine-mapped disease SNPs: single-score analysis
As a primary analysis, we analyzed 8,294 common and low-frequency SNPs (of 8,741 total SNPs) fine-mapped for 21 autoimmune diseases from Farh et al. 54 Classification of fine-mapped disease SNPs: multi-score analysis
We considered same 4 sets of SNPs as described above. We computed the AUROCs and AUPRCs jointly attained by:
• Annotations from the baseline-LD model We aggregated these scores by training a gradient boosting model (features: aggregated scores, labels: each of four sets of SNPs); we used odd (resp. even) chromosomes as training data to make predictions for even (resp. odd) chromosomes. We used the same training parameters as AnnotBoost (carefully selected to avoid over-fitting, consistent with the previous study 9,10 ) with hyperparameters tuned using a randomized search method with five-fold cross-validation. We report the average AUROC and AUPRC of odd and even chromosome classifiers. We note that no disease data (four sets of SNPs used as labels) was re-used in these analyses, as AnnotBoost uses only the input pathogenicity scores to generate positive and negative sets of training data. We assessed the significance of the difference between two AUROCs as in ref. 71 Table S2 . Results for standardized enrichment, defined as enrichment times the standard deviation of annotation value (to adjust for annotation size), are reported in Table S4 . . We report results for 6 genome-wide Mendelian scores (of 6 analyzed) for which annotations derived from published and/or boosted scores were marginally significant.
The percentage under each bar denotes the proportion of SNPs in the annotation; the proportion of top SNPs included in each annotation was optimized to maximize informativeness (largest |τ * | among Bonferronisignificant annotations, or top 5% if no annotation was Bonferroni-significant; top 5% was the average optimized proportion among significant annotations). Error bars denote 95% confidence intervals. In panel (B), * denotes marginally conditionally significant annotations. Numerical results are reported in Table S7 . Results for standardized enrichment, defined as enrichment times the standard deviation of annotation value (to adjust for annotation size), are reported in Table S4 . , we report results for the 10 most informative additional genome-wide scores (of 18 analyzed). In (C) and (D), we report results for the 10 most informative baseline-LD model annotations (of 47 analyzed). The percentage under each bar denotes the proportion of SNPs in the annotation; the proportion of top SNPs included in each annotation was optimized to maximize informativeness (largest |τ * | among Bonferroni-significant annotations, or top 5% if no annotation was Bonferroni-significant; top 5% was the average optimized proportion among significant annotations). Error bars denote 95% confidence intervals. In panels (B) and (D), * denotes marginally conditionally significant annotations. Numerical results are reported in Table S10 . Results for standardized enrichment, defined as enrichment times the standard deviation of annotation value (to adjust for annotation size), are reported in Table S4 . (A) (single-score analysis) We report the classification accuracy (AUROC) of each of the 82 boosted scores compared to the corresponding published score. We highlighted three scores: the score with the highest AUROC(published) (CpG content), the score with the highest AUROC(boosted) (Super-enhancer), and the score with the largest difference between AUROC(boosted) and AUROC(published) (Promoter). Scores with AUROC < 0.5 are displayed as AUROC = 0.5. (B) (multi-score analysis) We report the true positive rate vs. false positive rate and the classification accuracy (AUROC) of four aggregated scores. Numerical results are reported in Table S14 and Table S16 . Figure 5 . Informativeness for common disease of 11 jointly significant binary annotations from combined joint model. We report (A) heritability enrichment of 11 jointly significant binary annotations, meta-analyzed across 41 independent traits; (B) joint τ * values, conditioned on the baseline-LD model, 8 Roadmap annotations, and each other. We report results for the 11 jointly conditionally informative annotations in the combined joint model (S-LDSC τ * p < 0.0001 and |τ * | ≥ 0.25). The percentage under each bar denotes the proportion of SNPs in the annotation. Error bars denote 95% confidence intervals. Numerical results are reported in Table S18 . Results for standardized enrichment, defined as enrichment times the standard deviation of annotation value (to adjust for annotation size), are reported in Table S4 .
